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Abstract 
 
 
Background: The use of cannabis during the early stage of psychosis has been linked with 
increased psychotic symptoms. This study aimed to examine the use of cannabis in the 12 
months following a first-episode psychosis (FEP) and the link with symptomatic course and 
outcome over one year post psychosis onset.   
 
Method: 1027 FEP patients were recruited upon inception to specialised early intervention 
services for psychosis in the UK. Participants completed assessments at baseline, six and 
twelve months. 
 
Results: The results indicate that the use of cannabis was significantly associated with 
increased severity of psychotic symptoms, mania, depression and poorer psycho-social 
functioning. Continued use of cannabis following the first episode of psychosis was 
prognostic of outcome at one year. These associations were significant after adjusting for age, 
gender, DUP, age of psychosis onset, ethnicity and other drug use. 
 
Conclusion: This is the largest cohort study of first-episode psychosis patients receiving care 
within early intervention services. Cannabis use, in particular  continued use, is associated 
with poorer symptomatic and functional outcome during the first-episode of psychosis. The 
results highlight the need for effective and early intervention for cannabis use in FEP. 
 
 
Cannabis use, first‐episode psychosis, psychotic symptoms, prospective study 
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Introduction 
 
 
Psychosis is estimated to affect 3.5% of the population over a lifetime (van Os & Kapur, 
2009). The early stage, or first-episode of psychosis (FEP) is regarded as a ‘critical period’, 
important in determining the long-term outcome of psychosis (Birchwood, Todd & Jackson, 
1998). Loss of functioning and social disability occurs during the prodrome in adolescence 
and during the first two to three years of illness, and plateaus thereafter (McGlashan, 1996; 
Eaton, Thara, Federman, Melton & Liang, 1995). In addition, a longer duration of untreated 
psychosis (DUP) is associated with poorer functioning and quality of life as well as increased 
symptoms, including positive psychotic symptoms (Marshall et al., 2005).  
 
There is much unexplained variation in outcome in first-episode psychosis (van Os & Kapur, 
2009), therefore a greater need to understand factors that may be prognostic of outcome in 
FEP is important. One of these is the use of cannabis. Cannabis is widely used among people 
with psychosis (Green, Young & Kavanagh, 2005), and in FEP the rate of cannabis use has 
been found to range from 19% to 57% (Baeza et al., 2009; Barnett et al., 2007; Gonzales-
Pinto et al., 2011; Harrison et al., 2008;  Stone et al., 2014; Tosato et al., 2012). Research in 
FEP samples suggest that cannabis use may be associated with adverse outcome; such as 
increased positive symptoms (Addington & Addington, 2007; Grech Van Os, Jones, Lewis & 
Murray, 2005) and increased rates of psychotic relapse (Hides, Dawe, Kavanagh & Young, 
2006), whilst the cessation of cannabis use in FEP has been linked with significant 
improvements in positive and negative psychotic symptoms, general psychopathology and 
psycho-social functioning (Baeza et al., 2009; Clausen et al, 2014; González-Pinto et al., 
2011; Stone et al., 2014). A recent meta-analysis has also found that cannabis use may be 
associated with a younger age of psychosis onset (Large, Sharma, Compton, Slade & 
Nielssen, 2011). However, the majority of studies that have examined the impact of cannabis 
use have relatively small sample sizes, which may result in a lack of power to detect 
significant effects. Indeed, in a review of the literature the lack of statistical power in many 
studies has been acknowledged as a limitation, and this is often further compounded by high 
levels of attrition in longitudinal studies (Zammit et al., 2008). Furthermore, many studies 
have failed to control for potential confounding factors, such as alcohol and other drug use, 
which may result in an overestimation of the causal effects of cannabis use in psychosis 
(Zammit et al., 2008). Well-designed prospective cohort studies involving large clinical 
samples are needed to definitively determine whether cannabis use affects symptomatic 
outcome in psychosis.  
 
There is also some evidence which suggests that substance use (AI Green et al., 2004) and 
cannabis use (Schimmelmann et al., 2012) in FEP may be associated with longer DUP. As 
DUP is an established prognostic factor for outcome in psychosis (Marshall et al., 2005), this 
potential mediating effect of DUP warrants further investigation. A recently published review 
also suggests a potential association between the use of cannabis and mania: cannabis use 
may be linked with a younger age of mania onset, more frequent manic episodes and poorer 
outcome (Bally, Zullino & Aubry, 2014). However, there is little data regarding the impact of 
cannabis use on mania in FEP. 
 
This paper aims to examine the impact of cannabis use on the early course of psychosis, 
mania, depression and functioning in a large prospective sample of individuals with first-
episode psychosis over a period of 12 months after inception to treatment. We examine this 
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using recent data from the UK National EDEN project, a national, multi-site project that 
evaluated the effect of early intervention services for people with first-episode psychosis 
(Birchwood et al., 2014). 
  
It was hypothesised that:  
 
Cannabis use, and in particular, the continued use of cannabis, will be associated with greater 
psychotic symptoms and poorer psycho-social functioning at 12 months post psychosis onset. 
 
 
 
 
 
 
 
 
Method 
 
 
The National EDEN project aimed to evaluate the implementation and impact of Early 
Intervention Services on young people experiencing first episode of psychosis. The project 
was conducted within five geographical sites across England (Birmingham, Cambridge, 
Cornwall, Norwich, and Lancashire). The sample comprised all consecutive referrals from 
2005 – 2009. Participants were required to be aged between 14-35 years of age, with a first 
presentation of psychosis. For full details of the methodology see Birchwood et al. (2014). 
 
 
Measures 
Participants completed assessments at baseline, six months and twelve months after inception 
to treatment and substance use was assessed at baseline and 12 months. Assessments were 
conducted by research assistants who were not directly involved in clinical care.  
 
A complete overview of the assessments used in the National EDEN project is provided in 
the study protocol (Birchwood et al., 2014). For the purpose of this analysis data in relation to 
substance use, psychotic symptoms, mania, depression and psycho-social functioning were 
used.  
 
 
Substance use 
Lifetime substance use was assessed via client interview and review of patient records. 
Current substance use was defined as any use of drugs within the previous three months as 
assessed by a revised version of the Kavanagh Drug Check (Kavanagh, Saunders, Young, 
Jenner & Claire, 1998; Kavanagh et al., 2011). The measure was revised to include an 
additional item on the problem scale (‘Did your use of cannabis in the last three months result 
in you missing doses of medication?’). The level of dependence was assessed using the 
Severity of Dependence Scale (Gossop et al., 1995). 
 
 
Symptom measures 
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(i) The Positive and Negative Syndrome Scale (PANSS) (Kay, Fiszbein & Opler, 1987) was 
used to assess the severity of positive and negative symptoms of psychosis as well as the 
level of general psychopathology. The duration of untreated psychosis (DUP) was 
calculated for all clients upon entry to EIS.  
(ii) Mania was assessed using the eleven-item Young Mania Rating Scale (YMRS; Young, 
Biggs, Ziegler & Mayer, 1978).  
(iii)The level of depression was assessed using the nine-item Calgary Depression Scale for 
Schizophrenia (CDSS; Addington, Addington & Maticka-Tyndale, 1994). The scale has 
a high degree of specificity and is not confounded by the negative or extrapryramidal 
symptoms of psychosis.  
(iv) Psycho-social functioning was assessed using the Global Assessment of Functioning 
scale (GAF; Endicott, Spitzer, Fleiss & Cohen, 1976), a clinician rated scale for 
evaluating the level of psychological, social and occupational functioning  on a 
continuum from 0 – 100. The scale comprises an overall score as well as separate scores 
for the level of symptoms and disability (the latter two sub-scales are scored along a 
range of 0-90).  
 
 
 
 
Data Analysis 
Data were analysed using SPSS 19.0 and SAS 9.3 (SAS Institute, Cary NC).  
 
Chi-square was performed to examine change in the proportion of participants reporting the 
use of cannabis. Change in the level of dependence and cannabis related problems were 
assessed using the Wilcoxon Signed-Rank test. Association between the use of cannabis at 
baseline, and the age of psychosis onset and DUP was assessed using independent samples t-
tests and Mann-Whitney tests respectively.  
 
The association between reported cannabis use at each time point and the outcome of interest 
was estimated using generalised mixed models.  In the base model the outcome of interest 
was the response variable; age, gender, ethnicity, age at psychosis onset, duration of 
untreated psychosis and other drug use were explanatory variables.  In addition each subject 
provided information on the effect of cannabis at both time points, plus any additional effects 
of cannabis at the 1 year follow up (through fitting an interaction between phase and cannabis 
use).  Each subject provided data at study entry and 1 year, grouped using random intercept 
terms.  The inclusion of the interaction between treatment phase (1 year) and cannabis use at 
that phase was retained in the statistical model where it was associated with an improvement 
of at least 3.84 in the Akaike’s Information Criterion value (Akaike, 1974). 
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Results 
 
 
 
Participants 
1027 participants were recruited upon entry to treatment for first-episode psychosis. The 
sample was predominantly male (69%, n = 709), with a mean age of 23 (± 4.9). The majority 
of the sample were White British (73%, n = 750), unemployed (57%, n = 590), single (85%, 
n = 871) and living with parents (63%, n = 649). 
 
There was a 75.7% (n = 777) rate of participant retention at 12 months. There were no 
significant differences in age [p = 0.5], gender [p = 0.7], psychiatric diagnosis [p = 0.08], or 
the use of cannabis at baseline [p = 0.9] between participants that remained in the study and 
those lost to follow-up. An additional 1070 clients from early intervention services refused to 
take part in the study. There were no significant differences in age [p = 0.1] or gender [p = 
0.2] between participants that consented and those that refused to take part. 
 
 
Cannabis use over the first 12 months  
Sixty-four percent (n = 654) of participants reported lifetime use of drugs, with the use of 
cannabis accounting for most drug use (93%, n = 611). Cannabis users at baseline were found 
to be significantly younger than non-users (22.5 ± 4.6 years vs. 23.3 ± 5.0 years) [p = 0.02], 
and there was a significant association between cannabis use and gender [p < 0.001], with 
cannabis users 2.17 times more likely in males. 
 
There was a significant decrease in the use of cannabis between baseline (n = 279, 27%) and 
12 months (n = 178, 18%) [p < 0.001], accompanied by a significant decrease in the mean 
level of dependence (baseline: 4.38 ± 3.9; 12 months: 3.60 ± 3.8) [p = 0.02] and the mean 
level of drug related problems (baseline: 7.63 ± 5.7; 12 months: 4.70 ± 5.2) [p = 0.03] among 
participants that continued to use cannabis over the 12 month period. 
 
Data regarding the use of cannabis use at baseline and 12 months was available for 760 
participants. This indicates that 504 participants (66.3%), did not use cannabis at either time 
point, 16.8% (n = 128) of participants reported using cannabis at baseline and 12 month 
follow-up, 10.9% (n = 83) of participants stopped using cannabis and 5.9% (n = 45) reported 
starting cannabis use during the 12 month study period. 
 
 
Cannabis use, DUP, and age of psychosis onset 
The mean length of DUP was 308.02 days (± 632.89), with a mean age of psychosis onset of 
21.33 (± 4.99). Participants using cannabis at baseline were found to have a significantly 
younger age of psychosis onset (20.81 ± 4.7 years vs. 21.57 ± 5.0 years) [p = 0.03], and 
participants using cannabis at baseline may have a longer duration of DUP (358.9 ± 727.7 
days vs. 293.3 ± 600.9 days) [U = 90538.50; p = 0.055].  
 
 
 
 
 
Cannabis use and psychotic symptoms 
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The use of cannabis at either baseline or 12 month assessment was found to be associated 
with significantly higher symptoms in PANSS positive and total scores, mania and GAF 
symptoms, but not negative symptoms or depression. In line with our hypothesis, there were 
significant interactions between the use of cannabis and phase for PANSS positive, negative 
and total scores, depression and GAF disability, GAF symptom and GAF total scores, 
indicating a significant effect of continued cannabis use (see table 1). Thus for the PANSS 
total score for example, cannabis use at either time point was associated with an increase in 
the PANSS score at that time point of 3.2 units (95% CI 0.12 to 6.29).  In addition, using 
cannabis at the 1 year follow-up was associated with an additional 6.42 unit increase in 
PANSS total score (95% CI 2.31 to 10.53). 
 
The use of cannabis at baseline or 12 months assessment was found to be associated with a 
2.14 higher PANSS positive score (95% CI 1.41 to 2.88), but the interaction term between 
cannabis use and phase did not significantly improve model fit and thus was omitted in the 
final model.  The PANSS Negative score was not significantly affected at baseline in the 
presence of cannabis use, but the interaction between use at 12 months and the negative score 
was statistically significant with an increase of 2.12 points (95% CI 0.75 to 3.48). 
 
Cannabis use was associated with a worsened Young Mania score, but this did not differ 
according to phase.  Cannabis use at 12 months was associated with a substantially worsened 
Calgary Depression and GAF Disability scores. The GAF disability score was reduced both 
for the use of cannabis at either time period and additionally at 12 months.  While the GAF 
Total Score was reduced substantially at 12 months but not over both time periods. 
 
These associations were adjusted for age, gender, DUP, age of psychosis onset, ethnicity and 
other drug use. 
 
 
 
Table 1: Cannabis use and symptom severity 
Model Estimate Lower 95% CI Upper 95% CI P 
PANSS Total     
Cannabis 3.20 0.12 6.29 0.04 
Cannabis* Phase 6.42 2.31 10.53 0.002 
     
PANSS Positive     
Cannabis 2.14 1.41 2.88 <.0001 
     
PANSS Negative     
Cannabis -0.07 -1.11 0.97 0.90 
Cannabis* Phase 2.12 0.75 3.48 0.002 
     
Young Mania     
Cannabis 0.20 0.15 0.26 <.0001 
     
Calgary Depression     
Cannabis 0.05 -0.02 0.11 0.16 
Cannabis* Phase 0.13 0.05 0.21 0.002 
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GAF disability Scale     
Cannabis -1.13 -3.75 1.49 0.40 
Cannabis* Phase -6.01 -9.32 -2.69 0.0004 
     
GAF Symptom Scale     
Cannabis -3.27 -6.04 -0.49 0.02 
Cannabis* Phase -4.87 -8.55 -1.19 0.01 
     
GAF Total Scale     
Cannabis -1.05 -3.90 1.81 0.47 
Cannabis* Phase -7.76 -11.42 -4.10 <.0001 
 
 
 
 
 
Discussion 
 
 
 
This is the largest study to examine the link between cannabis use and first episode psychosis. 
The large sample size not only allowed us to detect a relationship between the use of 
cannabis, and the continued use of cannabis on psychotic symptoms and functioning, but also 
the magnitude of this effect. Consistent with other evidence (Large et al., 2011) this study 
also found the use of cannabis to be associated with a younger age of psychosis onset. 
 
We showed that the use of cannabis at either phase of assessment (baseline or 12 month 
follow-up) was associated with significantly higher scores in PANSS total and positive 
symptoms, Young mania and poorer GAF psycho-social functioning- symptoms. While the 
overall use of cannabis declined over time, we documented considerable variation with some 
participants (5.9%) initiating cannabis use and many (16.8%) continuing to use. There were 
highly significant cannabis X phase interactions indicating that the continued use of cannabis 
was associated with significantly greater symptoms for PANSS total scores, PANSS 
negative, Calgary depression, and GAF psycho-social functioning. These associations were 
adjusted for age, gender, DUP, age of psychosis onset, ethnicity and other drug use. 
 
The results of this study suggest that for PANSS total for example, the use of cannabis was 
associated with a 3.2 point increase in symptom severity, whilst the continued use of cannabis 
was associated with an additional 6.42 point increase in symptom scores. Taken together, this 
suggests that a person using cannabis at both baseline and 12 months would have a score that 
was 3.2 points higher at baseline and 9.62 points higher at 1 year. Similarly, for the positive 
symptoms of psychosis the data suggest that the use of cannabis was associated with a 2.14 
point increase in symptom scores, whilst for negative psychotic symptoms the continued use 
of cannabis was associated with a 2.12 increase in symptom severity.  
 
The increases in scores for the severity of symptoms linked to continued cannabis use 
represent clinically significant increases in symptomatology. Stable outpatients with 
psychosis typically have PANSS total scores of between 60 and 80 (Opler, Opler, & 
Malaspina, 2006). Therefore, an increase of 9.62 points as found in the current study 
represents a clinically significant increase in symptomatology, especially in light of 
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suggestions that even subtle symptom elevations as measured by the PANSS are predictive of 
deterioration (Opler et al., 2006). 
 
The relationship between the use of cannabis and the symptoms of mania in FEP has received 
relatively little attention in the research field: the current study found that cannabis use was 
associated with a 0.2 point increase in symptom scores for mania. The continued use of 
cannabis was also associated with a 0.13 point increase in symptom scores for depression.  
 
Previous research examining the impact of cannabis use in psychosis has typically focused on 
the effect of cannabis use on psychotic symptoms, but there is also some evidence to suggest 
that cannabis use may be associated with poorer psycho-social functioning (González-Pinto 
et al., 2011). Here we found continued cannabis use was associated with a 7.76 decrease (i.e. 
worse) total GAF score over the 12 months, suggesting continued cannabis use in FEP may 
be associated with poorer overall psycho-social functioning.  
 
Overall, our findings suggest that the use of cannabis, and in particular the continued use of 
cannabis, is associated with poorer symptomatic and functional outcome during the first-
episode of psychosis. The mechanism by which cannabis use exacerbates the symptoms of 
psychosis is not fully understood, although cannabis use may affect the metabolism and 
pharmokinetics of anti-psychotic medication (Linszen, Peters & de Hann, 2004), and may be 
associated with reduced medication compliance (Turkington et al., 2009). It has also been 
suggested that substance use during the early and prodromal stages of illness may mask the 
onset of psychotic symptoms and delay help seeking for psychosis, resulting in poorer 
outcome. The potential effect of DUP was controlled for in the main analysis. The current 
study found a significance level of p = 0.055 for cannabis use and longer DUP, indicating a 
potential association. It is suggested that this is explored in future research. 
 
It is also possible that the association between the use of cannabis and poorer symptomatic 
and functional outcome in this study is not the result of symptom exacerbation by cannabis 
use, but instead results from an attempt at self-medication, in that an increase in psychotic 
symptoms resulted in the onset or increase in the use of cannabis. However, this seems 
unlikely given that previous research has found increases in psychotic symptoms to be 
associated with decreased cannabis use (Fergusson, Horwood & Ridder, 2005) and self-report 
studies have consistently been unable to find any evidence that cannabis use in psychosis is 
the result of self-medication of psychotic symptoms (Fowler, Carr, Carter & Lewin 1998; 
Green, Kavanagh & Young, 2004; Schaub, Fanghaenal & Stohler, 2008). 
 
Previous research has found a significant effect of continued cannabis use on positive 
psychotic symptoms (Grech et al., 2005) and psychotic remission (Schimmelmann et al., 
2012), although studies have typically suffered from inadequate design, a lack of statistical 
power and high attrition rates (Zammit et al., 2008). This large scale prospective investigation 
suggests that the continued use of cannabis may adversely affect a range of symptomatic and 
functional domains in FEP, and also illustrates that the magnitude of this effect is clinically 
significant.  
 
This study is the largest prospective cohort study of first-episode psychosis patients treated 
routinely within specialised early intervention services. The results indicate that in spite of 
this ‘state of the art’ service, the use of cannabis, while declining during the early stage of 
psychosis, continues to exert a significant impact on symptomatic and functional outcome 
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and accordingly represents a key target for intervention and warrants further evaluation in 
prospective randomised studies. 
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